Kalbe Farma Tbk vs Prodia Diagnostic Line Tbk — how do they compare? Kalbe Farma Tbk trades at Rp800 (market cap 37.45T, 41.79M 24h volume), while Prodia Diagnostic Line Tbk trades at Rp270 (market cap 470.58B, 28.43M 24h volume). The key difference: Kalbe Farma Tbk is far larger — about 79.6× Prodia Diagnostic Line Tbk's market cap, and Kalbe Farma Tbk is more actively traded (41.79M versus 28.43M). Which is the better fit depends on your goals.
| KLBF | PRDL | |
|---|---|---|
Market Cap | 37.45T | 470.58B |
Volume | 41.79M | 28.43M |
Lot | 417.89K | 284.34K |
Turnover | 33.46B | 7.8B |
Average Price | 800.79 | 274.19 |
Value | 33.46B | 7.8B |
Indicative Equilibrium Price | 800 | 270 |
Indicative Equilibrium Volume | 18.3K | 2.1K |
Trailing returns across standard periods
Latest headlines on both assets
PT Kalbe Farma Tbk (the Company) was established in the Republic of Indonesia, within the framework of the Domestic Capital Investment Law No. 6 Year 1968, as amended by Law No. 12 Year 1970, basedon Notarial Deed No. 3 of Raden Imam Soesetyo Prawirokoesoemo datedon September 10th, 1966. The Company, which started commercial operation in 1966.
Read more on KLBF →PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →